Answers are grounded in this paper and cite their sources.
Observational cohort study shows high discontinuation rates in hidradenitis suppurativa patients on adalimumab, indicating treatment gaps.
Hidradenitis suppurativa (HS), a chronic, inflammatory skin disease, causes significant morbidity. Until 2023, adalimumab was the only US-approved biologic for patients with moderate to severe HS. This study describes the clinical profile, treatment utilization, and residual disease burden in patients with HS initiating adalimumab in the USA. This observational cohort study used data from the Merative MarketScan® Commercial, Medicare, and Multi-State Medicaid claims databases. Adult patients who initiated adalimumab treatment between 2015 and 2018 were included (main cohort). Patients required continuous insurance enrolment during the year prior to adalimumab initiation (baseline period). Patients were followed until adalimumab discontinuation or study end (2022) to examine treatment patterns, discontinuation rates, predictors of discontinuation, and healthcare resource utilization (HCRU). Study objectives were repeated from the onset of the coronavirus 2019 (COVID-19) pandemic (COVID-19 cohort; 2020–2022). Statistical methods included Kaplan–Meier estimates and a multivariable proportional hazard regression model. The main cohort included 2367 adult patients (70.4% Commercial/Medicare-insured and 29.6% Medicaid-insured). Overall, 60.3% of patients discontinued adalimumab and 6.5% of patients switched from adalimumab to other biologics; the drug survival at 6 and 12 months was 68.4% and 48.0%, respectively. Discontinuation predictors (based on baseline characteristics) included female sex, younger age, Medicaid insurance, and undergoing excision surgery. Despite a decrease in HCRU events during adalimumab treatment, the need for interventions such as antibiotics and surgeries persisted. The COVID-19 cohort showed similar trends in adalimumab drug survival and HCRU. While adalimumab improved certain outcomes in HS, residual burden and high discontinuation rates indicate the need for accessible and durable therapies. What Is Hidradenitis Suppurativa? Hidradenitis suppurativa, also referred to as HS, is a long-term skin disease that causes painful, swollen, and pus-filled areas in the skin. The disease has a large negative impact on quality of life. Adalimumab was the only medicine approved in the USA for the treatment of moderate to severe HS until 2023. However, patients continue to need other treatments on top of their treatment with adalimumab. What Did This Study Do? This study examined patients with HS in the USA who began adalimumab treatment from 2015 to 2021 to learn more about their healthcare needs while receiving adalimumab. The study used insurance records from adult patients to track their healthcare encounters and whether they stopped or continued the medication. Two groups of patients were studied. The main group were patients who began treatment from 2015 to 2018. To assess differences due to the COVID pandemic, a second group of patients who began treatment from 2020 to 2021 were also studied. What Were the Key Findings? Around six in ten patients stopped using adalimumab within a year of starting it. Women, younger patients, and those with Medicaid insurance were more likely to stop using adalimumab. Despite showing a reduction in the use of healthcare services, patients often still needed additional treatments such as antibiotics and even surgeries. A small group of patients also switched to other medicine types during the study. What Does This Mean? This study showed that while adalimumab helped patients manage their HS, there was still a large need for accessible treatments with a long-term effect.
No takes yet. Share an insight, caveat, or question.
Aleshin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: